The risk of subclinical valve leaflet thrombosis (SLT) following transcatheter aortic valve replacement (TAVR) did not differ regardless of whether patients received edoxaban or dual antiplatelet therapy (DAPT) post-surgery, according to results of the ADAPT-TAVR* trial.
Adding mavacamten – an allosteric modulator of cardiac myosin – to maximal medical therapy slashes the need for septal reduction therapy (SRT) in patients with obstructive hypertrophic cardiomyopathy (OHCM) who are candidates for such intervention, the VALOR-HCM trial has shown.
An annual influenza vaccination does not lower the risk of cardiovascular (CV) outcomes in patients with heart failure (HF), though it may reduce the risk of pneumonia and hospitalization, according to results of the IVVE study presented at ACC.22.
In individuals receiving renin-angiotensin-aldosterone system inhibitor (RAASi) therapy for heart failure with reduced ejection fraction (HFrEF), the novel potassium binder patiromer effectively reduced serum potassium levels, the DIAMOND trial suggests, thus optimizing a guideline-directed RAASi therapy for these patients.
Residual inflammation is a strong predictor of recurrent cardiovascular (CV) events than hyperlipidaemia in patients with atherosclerotic disease and impaired kidney function in a sub-study of the CANTOS* trial.
Patients with uncontrolled hypertension can benefit from renal sympathetic denervation, which leads to notable reductions in systolic blood pressure (SBP) after 6 months of intervention, reports the proof-of-concept SPYRAL HTN-ON MED trial presented at ACC.22.
Actively treating even mild hypertension to a target blood pressure (BP) of <140/90 mm Hg in pregnant women significantly lowers the risk of adverse pregnancy outcomes without apparent harm to the foetus compared with a strategy of reserving treatment to only when hypertension becomes severe (≥160/105 mm Hg), according to the CHAP* study presented at ACC 2022.
A pooled analysis of 13,171 patients from both the FIDELIO-DKD and FIGARO-DKD trials has confirmed the beneficial effects of finerenone, according to results of FIDELITY study, presented at the recently concluded American College of Cardiology Annual Scientific Session (ACC 2022).